about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Ap­ple Tree Part­ners leaps across the pond to launch a UK biotech look­ing to crack the se­crets of den­drit­ic cells

4 years ago
Financing
Startups

Bolt Bio goes bust as in­vestors boo sin­gle re­sponse in ear­ly test against HER2-ex­press­ing tu­mors

4 years ago
R&D

Adicet un­veils ear­ly re­spons­es for off-the-shelf drug lever­ag­ing rare T cells. Will dura­bil­i­ty hold up?

4 years ago
R&D
Cell/Gene Tx

Ae­glea's en­gi­neered en­zyme flops out­comes test in rare meta­bol­ic dis­ease. Is re­duc­ing a key bio­mark­er enough for an ...

4 years ago
R&D

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

4 years ago
Financing

Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

4 years ago
Deals
Discovery

Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

4 years ago
FDA+

Look­ing to run with Big Phar­ma, a ra­dio­phar­ma start­up with back­ing from At­las, RA thinks it has the chops to com­pete

4 years ago
Financing
Startups

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

4 years ago
People

Amid JAK de­ba­cle, Bris­tol My­ers set­tles in for FDA's long re­view of po­ten­tial first TYK2 drug

4 years ago
FDA+

Glax­o­SmithK­line places a risky bet on Ar­row­head­'s RNA drug in the fail­ure-strewn NASH field

4 years ago
Deals

Af­fimed spurs promis­ing re­sponse num­bers in NK cell study, but dura­bil­i­ty will be the big ques­tion

4 years ago
R&D
Cell/Gene Tx

Dai­ichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in ear­ly AML pa­tients

4 years ago
R&D

An RA-backed start­up 'AT­AC­s' a nov­el chal­lenge, look­ing to spur pro­tein degra­da­tion out­side the cell

4 years ago
Financing
Startups

Flag­ship's ma­chine learn­ing start­up Gen­er­ate bags $370M in lat­est round with plans for a big hir­ing spree

4 years ago
Financing

Cas­sava's prob­lems just got much worse as SEC launch­es probe in­to da­ta ma­nip­u­la­tion claims — re­port

4 years ago
R&D
FDA+

A Czech biotech bets big on ris­ing ADC play­er LegoChem as part of li­cens­ing pact aimed at sol­id tu­mors

4 years ago
Deals

Spurned by FDA on an­oth­er im­munother­a­py, Agenus holds up ear­ly da­ta for CT­LA-4 drug across tu­mor types

4 years ago
R&D

Wel­come to CPhI week: The drug man­u­fac­tur­ing in­dus­try's pre­mier con­fer­ence kicks off with the winds of change blow­ing

4 years ago
Outsourcing
Manufacturing

CPhI: As pan­dem­ic reach­es its fi­nal stages, an in­dus­try busier than ever re­flects on lessons learned

4 years ago
Outsourcing
Manufacturing

Chi­na's Zai Lab spins 2 more li­cens­ing deals, in­clud­ing a sud­den dive in­to neu­ro­science

4 years ago
Deals
China

A new Flag­ship start­up looks to crack tR­NA bi­ol­o­gy in search for com­plete­ly new class of ther­a­peu­tics

4 years ago
Financing
Startups

Mi­rati sees more re­spons­es for KRAS drug in Keytru­da com­bo as it an­gles for an edge over Am­gen

4 years ago
R&D

Bris­tol My­ers adds to neoad­ju­vant win for Op­di­vo in lung can­cer, es­ca­lat­ing ear­ly can­cer show­down with Mer­ck

4 years ago
R&D
Pharma
First page Previous page 1234567 Next page Last page
A service from the Financial Times